Search research articles
Contact Us
Filters
Showing results (101-110 of 129) with videos related to
Page
of 13
Sort By:
The New England Journal of Medicine
|
March 28, 2014
Ceritinib in ALK-rearranged non-small-cell lung cancer
Alice T Shaw, Dong-Wan Kim, Ranee Mehra, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
August 1, 2020
IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors
Lauren Giuffrida, Kevin Sek, Melissa A Henderson, et al.
Journal for Immunotherapy of Cancer
|
October 9, 2021
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
Peter Kar Han Lau, Breon Feran, Lorey Smith, et al.
Nature Medicine
|
January 15, 2020
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Alexander Drilon, Jeffrey W Clark, Jared Weiss, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 20, 2024
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer
Jonathan D Spicer, Tina Cascone, Murry W Wynes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2023
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
Daniel S W Tan, Enriqueta Felip, Gilberto de Castro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 10, 2024
Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer
Enriqueta Felip, Giulio Metro, Ross A Soo, et al.
The New England Journal of Medicine
|
June 4, 2013
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, et al.
The Lancet. Oncology
|
November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.
Nature Medicine
|
February 4, 2026
Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial
Benjamin Besse, Jessica J Lin, Lyudmila Bazhenova, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 129) with videos related to
Sort By:
Page
of 13
The New England Journal of Medicine
|
March 28, 2014
Ceritinib in ALK-rearranged non-small-cell lung cancer
Alice T Shaw, Dong-Wan Kim, Ranee Mehra, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
August 1, 2020
IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors
Lauren Giuffrida, Kevin Sek, Melissa A Henderson, et al.
Journal for Immunotherapy of Cancer
|
October 9, 2021
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
Peter Kar Han Lau, Breon Feran, Lorey Smith, et al.
Nature Medicine
|
January 15, 2020
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
Alexander Drilon, Jeffrey W Clark, Jared Weiss, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 20, 2024
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer
Jonathan D Spicer, Tina Cascone, Murry W Wynes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2023
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
Daniel S W Tan, Enriqueta Felip, Gilberto de Castro, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 10, 2024
Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer
Enriqueta Felip, Giulio Metro, Ross A Soo, et al.
The New England Journal of Medicine
|
June 4, 2013
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, et al.
The Lancet. Oncology
|
November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.
Nature Medicine
|
February 4, 2026
Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial
Benjamin Besse, Jessica J Lin, Lyudmila Bazhenova, et al.
Page
of 13